Literature DB >> 20505274

Castleman's disease of the retroperitoneum: with special reference to IgG4-related disorder.

Masaru Kojima1, Naoya Nakamura, Tadashi Motoori, Ken Shimizu, Yoshiro Otuski, Joji Haratake, Akira Ogawa, Tadahiko Igarashi, Nobuhide Masawa, Hiroshi Kobayashi, Shigeo Nakamura.   

Abstract

Localized Castleman's disease (CD) has been divided two types, the classical hyaline vascular (HV) type and the rare plasma cell (PC) type. Recently, we have reported two cases of IgG4-related disorder of the retroperitoneum showing PC type of CD. To further clarify the clinicopathological findings of CD of the retroperitoneum, eight such cases have been studied. A single lesion was located in the retroperitoneum (n=3), ureter (n=2) and renal hilum (n=2). One case had bilateral ureter lesions. The HV type of CD accounts for approximately 90% of cases. However, 50% (n=4) of our cases were the PC type of CD. Three of the four lesions of HV type had lymph node lesions, whereas all four PC type of CD were soft tissue masses. These clinicopathologic findings appear quite different from previous descriptions. Immunohistochemical study demonstrated numerous IgG4(+) plasma cells accounting for more that 50% of IgG4(+) cells in three cases of the four PC type of CD. Moreover, serum IgG4 concentration was increased in two of the four cases of PC type of CD that were examined. The serum interleukin-6 levels were within the normal range in two cases of PC type that were examined. The present study suggests that a majority of the PC type of CD arising in the retroperitoneum appears to be an IgG4-related disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505274     DOI: 10.3960/jslrt.50.39

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  8 in total

1.  Assessment of pathologically diagnosed patients with Castleman's disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease.

Authors:  Takaaki Ogoshi; Takashi Kido; Kazuhiro Yatera; Keishi Oda; Toshinori Kawanami; Hiroshi Ishimoto; Noriho Sakamoto; Arisa Sano; Chiharu Yoshii; Shohei Shimajiri; Hiroshi Mukae
Journal:  Lung       Date:  2013-08-13       Impact factor: 2.584

2.  Clinical characteristics of a concurrent condition of IgG4-RD and Castleman's disease.

Authors:  Xia Zhang; Panpan Zhang; Linyi Peng; Yunyun Fei; Wei Zhang; Ruie Feng; Wen Zhang
Journal:  Clin Rheumatol       Date:  2018-06-14       Impact factor: 2.980

Review 3.  IgG4-related disease of the ureter: report of two cases and review of the literature.

Authors:  Alessandro Marando; Gioacchino D'Ambrosio; Francesco Catanzaro; Stefano La Rosa; Fausto Sessa
Journal:  Virchows Arch       Date:  2013-05-11       Impact factor: 4.064

4.  Immunoglobulin G4-related lymphadenopathy with inflammatory pseudotumor-like features.

Authors:  Yasuharu Sato; Masaru Kojima; Katsuyoshi Takata; Xingang Huang; Eiko Hayashi; Akihiro Manabe; Yukari Miki; Tadashi Yoshino
Journal:  Med Mol Morphol       Date:  2011-09-16       Impact factor: 2.309

Review 5.  IgG4-related Disease - A Systemic Disease that Deserves Attention Regardless of One's Subspecialty.

Authors:  Hideaki Hamano; Eiji Tanaka; Nobukazu Ishizaka; Shigeyuki Kawa
Journal:  Intern Med       Date:  2017-12-27       Impact factor: 1.271

6.  Partial nephrogenic diabetes insipidus associated with Castleman's disease.

Authors:  Minah Kim; Hong Sang Choi; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim; Chang Seong Kim
Journal:  BMC Nephrol       Date:  2019-05-14       Impact factor: 2.388

7.  Historical and pathological overview of Castleman disease.

Authors:  Midori Filiz Nishimura; Yoshito Nishimura; Asami Nishikori; Tadashi Yoshino; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2022-04-27

8.  Castleman's disease in the retroperitoneal space mimicking a paraspinal schwannoma: a case report.

Authors:  Satoshi Nagano; Masahiro Yokouchi; Takuya Yamamoto; Hideyasu Kaieda; Takao Setoguchi; Tsubasa Hiraki; Yukie Tashiro; Suguru Yonezawa; Setsuro Komiya
Journal:  World J Surg Oncol       Date:  2013-05-23       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.